Evidence map›Paper›PMID 35786744›Full record

ArticleBrain : a journal of neurology2022

Defective lipid signalling caused by mutations in PIK3C2B underlies focal epilepsy.

Luca Gozzelino, Gaga Kochlamazashvili, Sara Baldassari, Albert Ian Mackintosh, Laura Licchetta, Emanuela Iovino, Yu Chi Liu, Caitlin A Bennett, Mark F Bennett, John A Damiano and 22 more

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 13 institutions in 4 countries.

Luca GozzelinoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.ORCID 0000-0001-9578-647X
Gaga KochlamazashviliDepartment of Molecular Pharmacology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Strasse 10, 13125 Berlin, Germany.
Sara BaldassariDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.ORCID 0000-0003-4851-2796
Albert Ian MackintoshDepartment of Molecular Pharmacology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Strasse 10, 13125 Berlin, Germany.
Laura LicchettaIRCCS Istituto delle Scienze Neurologiche di Bologna, Epilepsy Center (Reference Center for Rare and Complex Epilepsies-EpiCARE), Bologna, Italy.
Emanuela IovinoDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Yu Chi LiuEpilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
Caitlin A BennettEpilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
Mark F BennettEpilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.ORCID 0000-0002-3561-6804
John A DamianoEpilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
Gábor ZsurkaDepartment of Experimental Epileptology and Cognition Research and Department of Epileptology, University Bonn Medical Center, Venusberg Campus 1, D-53105 Bonn, Germany.
Caterina MarconiDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Tania GiangregorioDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Pamela MaginiU.O. Genetica Medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Marijn KuijpersDepartment of Molecular Pharmacology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Strasse 10, 13125 Berlin, Germany.
Tanja MaritzenDepartment of Molecular Pharmacology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Strasse 10, 13125 Berlin, Germany.
Giuseppe Danilo NorataDepartment of Excellence in Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan and Center for the Study of Atherosclerosis, SISA Bassini Hospital Cinisello B, Italy.
Stéphanie BaulacSorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, F-75013 Paris, France.
Laura CanafogliaUnit of Integrated Diagnostics for Epilepsy, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Marco SeriDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Paolo TinuperIRCCS Istituto delle Scienze Neurologiche di Bologna, Epilepsy Center (Reference Center for Rare and Complex Epilepsies-EpiCARE), Bologna, Italy.
Ingrid E SchefferEpilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
Melanie BahloSpedali Civili, Neuropsychiatric Department, Brescia, Italy.
Samuel F BerkovicEpilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.ORCID 0000-0003-4580-841X
Michael S HildebrandEpilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
Wolfram S KunzDepartment of Experimental Epileptology and Cognition Research and Department of Epileptology, University Bonn Medical Center, Venusberg Campus 1, D-53105 Bonn, Germany.
Lucio GiordanoSpedali Civili, Neuropsychiatric Department, Brescia, Italy.
Francesca BisulliIRCCS Istituto delle Scienze Neurologiche di Bologna, Epilepsy Center (Reference Center for Rare and Complex Epilepsies-EpiCARE), Bologna, Italy.ORCID 0000-0002-1109-7296
Miriam MartiniDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.ORCID 0000-0002-4262-946X
Volker HauckeDepartment of Molecular Pharmacology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Strasse 10, 13125 Berlin, Germany.ORCID 0000-0003-3119-6993
Emilio HirschDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.ORCID 0000-0002-9073-6024
Tommaso PippucciU.O. Genetica Medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
The University of Melbourne · AULeibniz-Forschungsinstitut für Molekulare Pharmakologie · DEIstituto delle Scienze Neurologiche di Bologna · ITMedica (Italy) · ITUniversity of Bologna · ITUniversity of Turin · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITCentre National de la Recherche Scientifique · FRLife & Brain (Germany) · DERoyal Children's Hospital · AUFondazione IRCCS Istituto Neurologico Carlo Besta · ITUniversity of Kaiserslautern · DEUniversity of Milan · IT

Funding

Center for Common Disease GeneticsUM1HG008895 · NHGRI · BROAD INSTITUTE, INC. · PI DALY, MARK JOSEPH, GABRIEL, STACEY · 2016 to 2020
$111.2M
NHGRI NIH HHS UM1 HG008895
6 · The paper itself

Abstract

Epilepsy is one of the most frequent neurological diseases, with focal epilepsy accounting for the largest number of cases. The genetic alterations involved in focal epilepsy are far from being fully elucidated. Here, we show that defective lipid signalling caused by heterozygous ultra-rare variants in PIK3C2B, encoding for the class II phosphatidylinositol 3-kinase PI3K-C2β, underlie focal epilepsy in humans. We demonstrate that patients' variants act as loss-of-function alleles, leading to impaired synthesis of the rare signalling lipid phosphatidylinositol 3,4-bisphosphate, resulting in mTORC1 hyperactivation. In vivo, mutant Pik3c2b alleles caused dose-dependent neuronal hyperexcitability and increased seizure susceptibility, indicating haploinsufficiency as a key driver of disease. Moreover, acute mTORC1 inhibition in mutant mice prevented experimentally induced seizures, providing a potential therapeutic option for a selective group of patients with focal epilepsy. Our findings reveal an unexpected role for class II PI3K-mediated lipid signalling in regulating mTORC1-dependent neuronal excitability in mice and humans.

Indexed as

Class II Phosphatidylinositol 3-KinasesEpilepsies, PartialAnimalsHumansLipidsMechanistic Target of Rapamycin Complex 1MiceMutationPhosphatidylinositol 3-KinasesSeizuresClass II Phosphatidylinositol 3-KinasesLipidsMechanistic Target of Rapamycin Complex 1Phosphatidylinositol 3-KinasesPIK3C2B protein, humanclass II PI3KepilepsymTORPI3K-C2Bvariants

Identifiers

PMID35786744
PMCPMC9337808
OpenAlexW4226286791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.